Partial Nephrectomy Preferable for T1a RCC
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
Urology Conferences
Certain Clinical Factors Up Risk for Urethral Stricture Complications
In a cohort study, 7% of patients had life-threatening complications associated with urethral stricture.
Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
First-Line Pembrolizumab for Cisplatin-Ineligible UC Has Durable Benefits
Longer follow-up of patients in the KEYNOTE-052 trial confirms the anti-tumor effect of first-line pembrolizumab in patients with cisplatin-ineligible advanced urothelial carcinoma.
Complete Response to Atezolizumab in UC Appears Durable
The median duration of complete response to atezolizumab in patients with locally advanced or metastatic urothelial carcinoma is more than 2 years, new data suggest.
Earlier Pembrolizumab Use May Be Beneficial in mUC
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
Enzalutamide Ups Survival in Metastatic Hormone-Sensitive PCa
Addition of enzalutamide vs another nonsteroidal anti-androgen to standard of care is associated with significant improvement in overall survival among men with metastatic hormone-sensitive prostate cancer.
PET/CT Imaging for Recurrent PCa Detection More Accurate With PSMA
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
More Advanced PCa Diagnoses Followed USPSTF Screening Recommendations
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
Visceral Metastases on the Rise in Metastatic Prostate Cancer
The proportion of men with metastatic prostate cancer who develop visceral metastases rose from 26% in 2009 to 40% in 2016, a study found.
Next post in Prostate Cancer
